Clinical Trials Browser

Phase 2/3 × Erlotinib Hydrochloride × Clear all

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT02926638 2020-03-19

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Phase 2/3 Terminated

9 enrolled 5 charts

MET Positive

NCT01407822 2018-09-11

EMERGING

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03074864 2017-03-09

TREND

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01383148 2017-01-05

TIME

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung